KINNATE BIOPHARMA INC's ticker is KNTE and the CUSIP is 49705R105. A total of 74 filers reported holding KINNATE BIOPHARMA INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 1.5%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $147,251 | -39.4% | 105,179 | +31.2% | 0.05% | -30.3% |
Q2 2023 | $242,942 | -52.0% | 80,179 | -1.0% | 0.07% | -56.6% |
Q1 2023 | $506,300 | +16.9% | 81,008 | +14.1% | 0.15% | +24.6% |
Q4 2022 | $433,149 | -53.6% | 71,008 | -9.1% | 0.12% | -51.4% |
Q3 2022 | $933,000 | -67.0% | 78,074 | -65.2% | 0.25% | -67.4% |
Q2 2022 | $2,830,000 | +69.7% | 224,451 | +51.5% | 0.77% | +77.2% |
Q1 2022 | $1,668,000 | -11.6% | 148,151 | +39.2% | 0.44% | -8.2% |
Q4 2021 | $1,886,000 | -23.1% | 106,453 | 0.0% | 0.47% | -27.1% |
Q3 2021 | $2,451,000 | +93.4% | 106,453 | +95.6% | 0.65% | +145.3% |
Q2 2021 | $1,267,000 | -23.2% | 54,415 | +2.8% | 0.26% | -32.2% |
Q1 2021 | $1,649,000 | -39.2% | 52,915 | -22.3% | 0.39% | -51.5% |
Q4 2020 | $2,710,000 | – | 68,121 | – | 0.81% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Foresite Capital Management IV, LLC | 9,671,643 | $225,156,000 | 30.44% |
Vida Ventures Advisors, LLC | 2,747,433 | $63,960,000 | 16.04% |
Foresite Capital Management V, LLC | 875,001 | $20,370,000 | 8.01% |
VR Adviser, LLC | 1,473,014 | $34,292,000 | 4.16% |
Logos Global Management LP | 1,329,602 | $30,953,000 | 2.60% |
RA Capital Management | 3,593,052 | $83,646,000 | 1.34% |
Orbimed Advisors | 3,847,929 | $89,580,000 | 0.91% |
Boxer Capital, LLC | 1,065,939 | $24,815,000 | 0.88% |
HARVARD MANAGEMENT CO INC | 498,001 | $11,593,000 | 0.67% |
HighVista Strategies LLC | 33,391 | $777,000 | 0.55% |